!
  + 
# Developing novel oral therapies for autoimmune, inflammatory, and neurodegenerative diseases
PROGRAM
Target
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
NLRP3 PORTFOLIO
 VTX2735
NLRP3Peripheral
Recurrent pericarditis
 VTX3232
NLRP3CNS-penetrant
Parkinson’s disease and cardiometabolic diseases
IBD PORTFOLIO
 Tamuzimod (VTX002)
S1P1R
Ulcerative colitis
 VTX958
TYK2
Crohn’s disease
## VTX2735: Peripherally restricted NLRP3 inhibitor for systemic autoinflammatory diseases and conditions
VTX2735 is a novel, highly potent, and selective oral inhibitor of NLRP3 with potential therapeutic benefit in a range of systemic inflammatory conditions including cardiovascular, metabolic, rheumatic, dermatologic, and rare genetic diseases. Initial clinical proof-of-concept for VTX2735 was established in a Phase 2 trial in patients with cryopyrin-associated periodic syndromes (CAPS), a genetic disease involving overactive NLRP3 (due to a naturally occurring gain-of-function mutation in the NLRP3 gene). Treatment with VTX2735 led to meaningful improvement in both inflammatory biomarkers and patient-reported symptom scores in this rare disease indication. These clinical data provide a strong therapeutic rationale for other diseases in which NLRP3 is aberrantly activated.
### VTX2735 in recurrent pericarditis (RP) and cardiovascular disease
NLRP3 inhibition is emerging as a compelling therapeutic approach for multiple cardiovascular conditions, offering the potential to selectively modulate IL-1β and induce downstream effects on other inflammatory markers such as IL-6 and CRP with a safe, convenient oral therapy. Ventyx has selected recurrent pericarditis as the initial cardiovascular indication for VTX2735.
Recurrent pericarditis is a rare, debilitating autoinflammatory condition affecting approximately 40,000 patients in the US alone. The inflammatory process in RP is characterized by IL-1α/β release (indirectly and directly downstream of NLRP3, respectively), driving inflammation in the pericardium, the fluid-filled sac surrounding the heart. Rilonacept, an injectable IL-1α/β cytokine trap, became the first FDA-approved therapy for RP in 2021, validating the anti-IL-1α/β approach in RP. A peripheral NLRP3 inhibitor such as VTX2735 may be an effective therapy for the treatment and prevention of recurrent pericarditis, offering a safe, oral option for patients living with RP.
## VTX3232: Novel CNS-penetrant NLRP3 inhibitor with best-in-class potential in NLRP3-mediated neuroinflammatory and neurodegenerative diseases
VTX3232 is currently in Phase 2 trials for the treatment of Parkinson’s disease and obesity-associated cardiometabolic diseases.
VTX3232 is an oral, selective, CNS-penetrant NLRP3 inhibitor with potential therapeutic utility for a range of neuroinflammatory diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and cardiometabolic diseases.
First-generation NLRP3
inhibitors have poor
inherent blood-brain
barrier permeability and
require high systemic
doses to achieve
CNS efficacy.
VTX3232 is rationally
designed for rapid
equilibration across
the BBB, efficiently
reaching target cells
in the brain.
[Learn more about the scientific
rationale of targeting NLRP3
### VTX3232 in Parkinson’s disease (PD)
There is a growing body of preclinical evidence implicating microglial NLRP3 activation as an important axis in PD pathogenesis. Preclinical models and PD patient samples strongly implicate NLRP3-mediated neuroinflammation as a key driver of neuronal degeneration in PD. Inhibition of NLRP3 in the CNS may provide a disease-modifying therapeutic approach with potential to prevent dopaminergic neurodegeneration and clinical progression in PD.
### VTX3232 in obesity-associated cardiometabolic diseases
NLRP3-mediated inflammation has been implicated in obesity and metabolic disorders, including insulin resistance, diabetes, and atherosclerosis, which are all potentially linked to NLRP3 -derived cytokines such as IL-1β and IL-6 in the periphery. NLRP3-mediated neuroinflammation in the hypothalamus has also been proposed as playing a significant role in obesity and obesity-related cardiometabolic dysfunction. Reducing NLRP3-mediated chronic inflammation, both systemically and in the CNS, with VTX3232 could be an important new method for treating these conditions.
## Tamuzimod: Potential best-in-class S1P1R modulator for ulcerative colitis (UC)
Tamuzimod is a selective S1PR1 modulator that, in a 52-week Phase 2 trial, demonstrated a potential best-in-class profile in UC, with a potential best-in-disease safety profile amongst all the oral options for UC therapy. Tamuzimod showed high rates of clinical remission and endoscopic remission which may position this drug as the backbone of future advanced combination treatment for UC, offering an effective and well-tolerated alternative for achieving optimal disease control in selected patients.
## VTX958: An oral, selective, allosteric TYK2 inhibitor
TYK2 regulates both innate and adaptive immunity by mediating type I interferon, IL-12, and IL-23 signaling. Selectively targeting inhibition of TYK2 without inhibition of other JAK family enzymes provides an optimal balance between reducing inflammation and preserving immune protection.
VTX958 has been evaluated in Phase 2 trials in psoriasis and Crohn’s disease. Further development of VTX958 in IBD is currently being evaluated.
## Expanded access
Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with a serious or life-threatening disease or condition to try an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when there are no comparable or satisfactory therapies available. Expanded access may be appropriate when all the following apply:
* Patient has a serious or immediately life-threatening disease or condition.
* There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
* Patient enrollment in a clinical trial is not possible.
* Potential patient benefit justifies the potential risks of treatment.
* Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
At this time, Ventyx Biosciences, Inc., and its affiliates (referred to as Ventyx), are unable to provide their investigational medicines on an expanded access or right to try basis.
To determine if you qualify for a clinical trial of a Ventyx investigational product, please visit .
Contact us
info@ventyxbio.com
© 2025 Ventyx Biosciences, Inc. All rights reserved.
# Building a company to make a difference in patients’ lives
 At Ventyx, we’re growing a leading biopharmaceutical company focused on developing therapeutics to improve the lives of patients and the people who love them. Everything we do revolves around advancing our clinical- and discovery-stage drug candidates, designed to help patients living with a range of inflammatory and autoimmune disorders.
Located in Del Mar, California, we pride ourselves on competitive salary and benefits and on our supportive and collaborative work environment, where people can advance their careers and have a big impact. If you are looking for a place where you can learn and grow, while working alongside a great team, we’d love to hear from you at careers@ventyxbio.com or view our job openings below.
 We are looking for science-driven individuals prepared to focus on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders
**Notice to Recruiters and Agencies:**
The Human Resources team manages the recruitment and employment process for Ventyx Biosciences. To protect the interest of all parties involved, Ventyx Biosciences does not accept unsolicited referrals or resumes from any source other than directly from candidates. We will not consider unsolicited referrals and/or resumes from vendors including and without limitation, search firms, staffing or recruiting agencies, or fee-based referral services. The submission of referrals or resumes by anyone other than a candidate directly to Ventyx Biosciences’ employees is strictly prohibited. Unsolicited referrals and resumes sent to Ventyx are deemed gratuitous, and do not obligate Ventyx to pay fees should we hire from those resumes. Recruiters are requested not to contact or present candidates directly to our hiring managers or employees. Please direct all inquiries to careers@ventyxbio.com.